ABT-110
ABT-110 is an investigational drug developed by AbbVie, a global biopharmaceutical company. It is primarily studied for its potential therapeutic effects in treating certain types of cancer. ABT-110 is classified as a small molecule inhibitor, targeting specific pathways involved in cancer cell proliferation and survival.
Mechanism of Action[edit | edit source]
ABT-110 functions by inhibiting specific proteins that are crucial for the growth and survival of cancer cells. It is designed to interfere with the signaling pathways that promote tumor growth, thereby inducing apoptosis, or programmed cell death, in cancerous cells. The exact molecular targets of ABT-110 are proprietary, but it is known to affect pathways commonly dysregulated in cancer.
Clinical Development[edit | edit source]
ABT-110 is currently in the early stages of clinical development. Preclinical studies have shown promising results in vitro and in animal models, demonstrating its potential efficacy in reducing tumor size and inhibiting metastasis. The drug is undergoing Phase I clinical trials to evaluate its safety, tolerability, and pharmacokinetics in humans.
Potential Indications[edit | edit source]
While the primary focus of ABT-110 is on oncology, particularly in solid tumors, research is ongoing to explore its efficacy in other indications. The drug's ability to target specific cancer pathways makes it a candidate for combination therapy with other anticancer agents.
Side Effects and Safety[edit | edit source]
As with many investigational drugs, the safety profile of ABT-110 is still being established. Common side effects observed in early trials include mild to moderate nausea, fatigue, and headache. Serious adverse effects are rare but are being closely monitored as clinical trials progress.
Research and Future Directions[edit | edit source]
Ongoing research aims to better understand the pharmacodynamics and pharmacokinetics of ABT-110, as well as its long-term effects on patients. Future studies will likely focus on optimizing dosing regimens and exploring its use in combination with other therapies to enhance its anticancer effects.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
